InsidersTradesSigma
Track the Korro Bio, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €195.3m. The latest transaction was disclosed on 28 August 2026 (Cession). Among the most active insiders: FORMELA JEAN FRANCOIS. Every trade is free.
90
Insider Decl.
n/a
Thresholds
€27m
22 ops.
Buy Volume
€2m
27 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Korro Bio, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$20.20.
45Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 28 August 2026
Declarations90 total
249 shares@ US$13.96Common StockSEC:0001030575-26-000012:0
51 shares@ US$13.96Common StockSEC:0001030575-26-000012:1
249 shares@ US$13.730.0018% mcap0.1% of flowCommon StockSEC144:0001628280-26-059122
51 shares@ US$13.730.0004% mcap0.0% of flowCommon StockSEC144:0001628280-26-059121
23,584 shares@ US$14.000.16% mcap10.6% of flowCommon StockSEC:0001030575-26-000010:0
4,884 shares@ US$14.000.034% mcap2.2% of flowCommon StockSEC:0001030575-26-000010:1
23,584 shares@ US$13.220.15% mcap8.1% of flowCommon StockSEC144:0001628280-26-058030
4,884 shares@ US$13.220.032% mcap3.4% of flowCommon StockSEC144:0001628280-26-058029
1,775 shares@ US$13.960.013% mcap0.9% of flowCommon StockSEC:0001030575-26-000008:0
368 shares@ US$13.960.0026% mcap0.2% of flowCommon StockSEC:0001030575-26-000008:1
5,222 shares@ US$11.39980.030% mcap70.6% of flowCommon stock, $0.001 par value per shareSEC:0000902664-26-003434:0
Canonical exit: 4 Nov 2026 (T+90)
1,462 shares@ US$13.18690.0098% mcap22.9% of flowCommon stock, $0.001 par value per shareSEC:0000902664-26-003434:1
Canonical exit: 8 Nov 2026 (T+90)
1,775 shares@ US$13.490.012% mcap0.7% of flowCommon StockSEC144:0001628280-26-055858
368 shares@ US$13.490.0025% mcap0.3% of flowCommon StockSEC144:0001628280-26-055859
7,500 shares0Common StockSEC:0001193125-26-306733:0
5,500 shares0Common StockSEC:0001193125-26-306742:0
6,500 shares0Common StockSEC:0001193125-26-306739:0
7,500 shares0Common StockSEC:0001193125-26-306743:0
85,955 shares@ US$14.030.59% mcap45.4% of flowCommon StockSEC:0001030575-26-000006:0
14,745 shares@ US$14.030.10% mcap7.8% of flowCommon StockSEC:0001030575-26-000006:1
817 shares@ US$13.960.0056% mcap0.4% of flowCommon StockSEC:0001030575-26-000006:2
8,506 shares@ US$13.960.058% mcap4.5% of flowCommon StockSEC:0001030575-26-000006:3
817 shares@ US$14.000.0056% mcap1.0% of flowCommon StockSEC144:0001628280-26-047352
25 of 90 declarations
Acerca de Korro Bio, Inc.
Korro Bio, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias basadas en la edición de ARN. Cotiza en NASDAQ bajo el símbolo XNAS.